ROCHESTER, Minn. — Mayo Clinic researchers have developed a new, personalized approach to deep brain stimulation (DBS) for people with drug-resistant epilepsy. By mapping each patient's unique brain wave patterns, the method allows physicians to target the precise area in the brain where stimulation is most effective, moving beyond the traditional one-size-fits-all approach.

DBS involves implanting electrodes in the brain to deliver electrical pulses that help prevent and control seizures. While effective, DBS is typically administered with electrodes placed in the same brain region across most patients. Mayo Clinic physician-scientists are now tailoring the treatment to an individual's seizure network before DBS placement.

"Our unique approach aims to tailor neuromodulation for each patient," says Nick Gregg, M.D., a Mayo Clinic neurologist and lead author of a paper published in the Annals of Neurology. "We're moving away from one-size-fits-all to an individualized approach that maximizes seizure network engagement to better modulate abnormal brain wave activity."

Once researchers identify the specific area in the thalamus — a small relay hub deep within the brain — that connects to a patient's seizure network, they can fine-tune stimulation settings for that individual. Because seizures occur infrequently, clinicians analyze erratic brain wave patterns that signal abnormal activity.

"We're trying to disrupt the pathological hypersynchrony and reduce network excitability to lower seizure risk," says Dr. Gregg.

Ten patients received this personalized approach while being evaluated for epilepsy surgery. The next phase of research will follow those who have since received permanent DBS implants using this personalized approach.

"The long-term goal is to quiet the seizure network, so it is eventually forgotten. Reorganizing the neuronal network could move us beyond controlling seizures to actually curing epilepsy."

This research is part of Mayo Clinic's Bioelectronic Neuromodulation Innovation to Cure (BIONIC) initiative, which unites clinical insight with cutting-edge engineering to deliver novel diagnostics and therapies. Through intellectual property development, strategic partnerships and patient-centered trials, BIONIC transforms innovation into impact — advancing care for complex neurological conditions.

Dr. Gregg's research was supported by the Tianqiao & Chrissy Chen Institute. Review the study for a complete list of authors, disclosures and funding.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

Media contact:

• Tia Ford, Mayo Clinic Communications, newsbureau@mayo.edu

The post Mayo Clinic physicians map patients’ brain waves to personalize epilepsy treatment appeared first on Mayo Clinic News Network.

ROCHESTER, Minn. — Mayo Clinic researchers have developed a new tool that can estimate a person's risk of developing memory and thinking problems associated with Alzheimer's disease years before symptoms appear. The research, published in The Lancet Neurology, builds on decades of data from the Mayo Clinic Study of Aging — one of the world's most comprehensive population-based studies of brain health.

The study found that women have a higher lifetime risk than men of developing dementia and mild cognitive impairment (MCI), a transitional stage between healthy aging and dementia that often affects quality of life but still allows people to live independently. Men and women with the common genetic variant, APOE ε4, also have higher lifetime risk.

Predicting Alzheimer's disease

Alzheimer's disease is marked by two key proteins in the brain: amyloid, which forms plaques, and tau, which forms tangles. Drugs recently approved by the Food and Drug Administration remove amyloid from the brain and can slow the rate of disease progression for people with MCI or mild dementia.

"What's exciting now is that we're looking even earlier — before symptoms begin — to see if we can predict who might be at greatest risk of developing cognitive problems in the future," says Clifford Jack, Jr., M.D., radiologist and lead author of the study.

The new prediction model combined several factors, including age, sex, genetic risk as associated with APOE genotype and brain amyloid levels detected on PET scans. Using the data, researchers can calculate an individual's likelihood of developing MCI or dementia within 10 years or over the predicted lifetime. Of all the predictors evaluated, the brain amyloid levels detected on PET scans was the predictor with the largest effect for lifetime risk of both MCI and dementia.

"This kind of risk estimate could eventually help people and their doctors decide when to begin therapy or make lifestyle changes that may delay the onset of symptoms. It's similar to how cholesterol levels help predict heart attack risk," says Ronald Petersen, M.D., Ph.D., neurologist and director of the Mayo Clinic Study of Aging, who is a co-author of the study.

The research stands apart because it draws from the Mayo Clinic Study of Aging, a long-running effort in Olmsted County, Minnesota, that tracks thousands of residents over time. The analysis for this study included data from 5,858 participants. Unlike most studies, Mayo researchers are able to continue following participants even after they stop actively taking part, using medical record data — ensuring nearly complete information about who develops cognitive decline or dementia.

"This gives us a uniquely accurate picture of how Alzheimer's unfolds in the community," says Terry Therneau, Ph.D., who led the statistical analysis and is the senior author of the study. "We found that the incident rate of dementia was two times greater among the people who dropped out of the study than those who continued to participate."

The study elevates the significance of MCI, which is the stage targeted by current Alzheimer's drugs that slow but do not stop progression.

While the new tool is currently a research instrument, it represents a major step toward more personalized care. Future versions may incorporate blood-based biomarkers, which could make testing more accessible.

The work was supported by the National Institute on Aging, the GHR Foundation, Gates Ventures and the Alexander Family Foundation.

The research is part of a larger effort at Mayo Clinic called the Precure initiative focused on developing tools that empower clinicians to predict and intercept biological processes before they evolve into disease or progress into complex, hard-to-treat conditions.

"Ultimately, our goal is to give people more time — time to plan, to act and to live well before memory problems take hold," says Dr. Petersen.

Review the study for a complete list of authors, disclosures and funding.

### 

About Mayo Clinic 
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news. 

Media contact:

• Tia Ford, Mayo Clinic Communications, newsbureau@mayo.edu

The post Mayo Clinic scientists create tool to predict Alzheimer’s risk years before symptoms begin appeared first on Mayo Clinic News Network.

November is Epilepsy Awareness Month

PHOENIX — Medication has long been the cornerstone of treatment for people with epilepsy, but it doesn't stop seizures for everyone and may come with significant side effects. New options in use or under development include devices and gene and cell therapies aimed at resetting or rehabilitating the brain circuits that cause seizures, explains Dr. Jonathon Parker, a neurosurgeon at Mayo Clinic in Phoenix and director of the Device-Based Neuroelectronics Research Lab.

The objective is a personalized approach that provides patients with the safest, most effective treatment options for them, Dr. Parker says.

"Epilepsy on its own is very impactful on quality of life. You have these intermittent, unpredictable events or spells — electrical storms in the brain — that can affect your ability to communicate and control your body. Often, people lose consciousness," he says. "It's a really challenging disease to live with."

Medication controls seizures in many patients, but it can come with side effects such as sleepiness, cognitive changes, mood changes and a feeling of mental fogginess, further affecting quality of life, Dr. Parker explains.

Epilepsy is one of the world's most common neurological diseases. Roughly 50 million people have it, global statistics show. It can affect anyone of any age. Possible causes include genetics, brain damage, brain tumors, stroke and other blood vessel diseases, and some infections. Often, the cause of a person's epilepsy remains unknown.

"In up to one-third of patients with epilepsy medications eventually fail to control seizures," Dr. Parker says. In those cases, surgery to remove or ablate the part of the brain causing seizures has typically been the next option explored, he adds. In ablation, laser energy is channeled to disable epileptic tissue.

"However, there has been a paradigm shift and now we have new options to try to electrically rehabilitate abnormal circuitry that's causing seizures, a type of treatment called neuromodulation," Dr. Parker says. "And we're investigating regenerative therapies to try to get to the root cause and repair the brain at the cellular or molecular level rather than remove brain tissue or reset the brain."

Neuromodulation

Using deep brain stimulation techniques, neuroscientists at Mayo Clinic are looking for early signals in the brain to help stop seizures. In their biomarker discovery initiative, a team of researchers assesses how different stimulation patterns affect different parts of the brain.

"We're looking for that brain signal fingerprint that yes, these are the right stimulation settings that are pushing the brain toward a state where seizures are less likely," Dr. Parker says. "For patients having multiple attacks, sometimes per day or per week, if we're able to dramatically reduce them, it allows them to live their life in a much more predictable fashion, easier for them to do the things that they like to do in life without having to live in fear of these uncontrolled neurological attacks."

Deep brain stimulation involves implanting electrodes in the brain that produce electrical impulses to treat certain medical conditions, such as epilepsy. The team includes engineers, clinicians and neuroscientists who analyze the brain's electrical signals and extract meaning for the right settings for an individual patient's deep brain stimulation device.

Neural cell therapy

Dr. Parker and colleagues are studying cell-based therapies to help the brain restore its ability to regulate its electrical activity.

"You can think of epilepsy at some level as a disorder of abnormal regulation of brain neurons. In a healthy brain, some things excite the brain, and some things inhibit the brain. There's a never-ending balance of exciting neurons and quieting neurons down that allows the brain to function normally," he explains.

In people with epilepsy, the brain sometimes loses interneurons, the neurons that slow things down.

"You have this tendency for neurons to get very excited and then draw other neurons into that, creating a rhythmic electrical activity in the brain known as a seizure," Dr. Parker says.

The idea behind cell therapy is to transplant interneurons into the area of the brain affected by epilepsy, the temporal lobe, so the interneurons persist and help to restore the normal balance, he says.

Gene therapy

Dr. Parker is co-leader of a Mayo research team investigating potential gene therapy for epilepsy.

The approach in gene therapy is to look at specific ion channels or proteins in cells that control whether a cell is going to be active or inactive, he explains. In epilepsy, some of those gatekeepers do not work normally.

"They open and close incorrectly, or they stay open or close too long. Neurons get excited, and that excitement spreads in an uncontrolled fashion and a seizure happens," Dr. Parker says.

The team is studying the use of an adenovirus, a common virus in the body, to deliver therapy to reduce the activity of genes in the part of the brain where seizures are coming from, he says. 

"The options that we have are changing," Dr. Parker says. "They're improving year after year."

For more information about innovations in epilepsy care, visit mayoclinic.org.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

Media contact:

• Sharon Theimer, Mayo Clinic Communications, newsbureau@mayo.edu

The post Innovation in epilepsy care: Alternatives to medication seek to reset, repair brain, expert explains appeared first on Mayo Clinic News Network.

World Heart Day is September 29

ROCHESTER, Minn. — You may have heard of the mind-body connection: the broad concept that  thoughts and feelings, especially those related to stress, can influence physical health. Mohamad Alkhouli, M.D., an interventional cardiologist at Mayo Clinic in Rochester, Minnesota, is researching the relationship between the brain and the heart. Each can have a powerful impact on the other, Dr. Alkhouli explains.

"The mind-heart connection is part of the broader mind-body relationship, but it’s uniquely powerful. Emotional states like anxiety, grief, or even joy can directly influence heart rhythms, blood pressure, and even the risk of heart attacks," Dr. Alkhouli says. "At the same time, the heart sends signals back to the brain through nerves, hormones, and pressure receptors — affecting our mood, attention, and stress levels. So, it’s not just the brain talking to the heart; the heart talks back."

Conditions with a brain-heart connection include spontaneous coronary artery dissection (SCAD) and stress-induced cardiopathy (SICM), also known as broken heart syndrome. Both conditions can result from stress. Dr. Alkhouli has been part of Mayo Clinic research teams exploring aspects of each.

Broken heart syndrome often is sparked by stressful situations and extreme emotions; it briefly interrupts the way the heart pumps blood. People experiencing it may have sudden chest pain and think they're having a heart attack.

The tools typically used to screen for heart attacks cannot identify when broken heart syndrome is actually the cause of a patient's chest pain. In most cases, invasive coronary angiography is required to differentiate SICM from myocardial infarction due to coronary obstruction. Mayo research found that a novel technology called magnetocardiography, which measures magnetic fields generated by the heart, can help identify broken heart syndrome. 

Another Mayo study suggests that SCAD, a type of heart attack that often results from physical or emotional stress, can be a secondary event instigated by broken heart syndrome.

In broken heart syndrome, the heart's temporary weakening doesn't happen evenly: Some parts of the heart fail to contract well, while others work harder to compensate, Dr. Alkhouli says. This uneven motion creates twisting forces on the heart muscle. 

"Because the coronary arteries, the main blood vessels that supply blood to the heart, sit on top of the heart, they can be stretched or stressed at the junctions between these overactive and underactive areas during broken heart syndrome," he explains. "In some cases, this stress may cause a tear in the artery wall, what we call SCAD."

A question still to be answered is why some people develop broken heart syndrome after emotional trauma while others do not, Dr. Alkhouli notes.

Emotional stress also can increase the risk of other heart conditions, such as:

• High blood pressure, also known as hypertension.
• Heart disease.
• Atrial tachycardia.
• Bradycardia.

"What fascinates me most is how deeply intertwined our emotional and cardiovascular systems are, and how much we still don't understand," Dr. Alkhouli says. "Could we one day 'rewire' this connection for healing, using therapy, neuromodulation (alteration of nerve activity at targeted sites in the body by electrical or chemical means), or even digital tools? At Mayo Clinic, we're exploring these questions, and we're beginning to see the heart and brain not as separate organs, but as a single, dynamic network."

That network works in both directions. Dr. Alkhouli is part of Mayo's Heart Brain Clinic, where cardiologists and neurologists work together to evaluate patients who may have neurological symptoms that can be attributed to a cardiac event.

In these patients, the heart and brain are closely linked, such as strokes caused by clots that form in the heart, known as cardioembolic strokes. The causes of a transient ischemic attack, a short period of stroke-like symptoms, may include a blood clot that moves from another part of the body, such as the heart, to an artery that supplies the brain. The heart condition atherosclerosis, the buildup of fats, cholesterol and other substances in and on the artery walls, can also lead to a transient ischemic attack.  

More research is needed to better understand how to harness the mind-heart connection for disease prevention and healing. There are steps you can take now for your mental health that will benefit your heart, and things you can do for your heart health that will benefit your brain, Dr. Alkhouli says.

"The good news is that what's good for your mind is often good for your heart, and vice versa," he explains. That includes:

• Managing stress.
• Getting quality sleep.
• Staying socially connected.
• Practicing mindfulness or prayer.

"All have measurable benefits for heart health," Dr. Alkhouli says. "Likewise, regular physical activity, a heart-healthy diet and controlling blood pressure and cholesterol can boost mood and cognitive function. It's a powerful feedback loop: Caring for one supports the other."

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

Media contact:

• Sharon Theimer, Mayo Clinic Communications, newsbureau@mayo.edu

The post The brain-heart connection: Mayo Clinic expert explains powerful tie that works both ways appeared first on Mayo Clinic News Network.

Before the sun rises at his home near Orlando, Florida, Rakesh Parekh, M.D., is already making the most of the day. He reviews patient notes and exercises before joining his wife, Tejal Parekh, in preparing their children for school. Time means a great deal to Dr. Parekh.

In 2020, he was diagnosed with amyotrophic lateral sclerosis (ALS) after muscle weakness began to affect his movement. ALS is a nervous system disease that affects nerve cells in the brain and spinal cord. Worsening over time, ALS affects control of the muscles needed to move, speak, eat and breathe.

Watch: Dr. Rakesh Parekh's story

Journalists: Broadcast-quality video pkg (2:16) is in the downloads at the end of the post. Please courtesy: "Mayo Clinic News Network." Read the script.

"You get this diagnosis, and, you know, within three to five years, you're no longer," says Dr. Parekh.

He was familiar with the disease long before his own diagnosis.

"My father lived with ALS," says Dr. Parekh. "I know time is of the essence."

Initially working with a care team closer to home, Tejal and Dr. Parekh were determined to find a way forward to preserve his quality of life and possibly help others, including their children, who have a chance of inheriting the gene mutation. The couple began messaging physicians, researchers and friends around the world. That's when they learned about the work of Dr. Bjorn Oskarsson, a Mayo Clinic neurologist.

"Dr. Oskarsson was recommended to us by a friend, and it was like finding a diamond in the rough," says Tejal Parekh.

A personalized approach

Dr. Oskarsson and colleagues at Mayo Clinic have spent their careers looking for answers and options for people diagnosed with ALS. A multidisciplinary care team met with Dr. Parekh in May 2021 and began tests to determine the best way forward.

"We worked with our outside partner to develop an individualized treatment made just for him," says Dr. Oskarsson.

The therapy aims to stop protein production by targeting the gene mutation and halting the progression of the disease. After nearly two years of testing and preparations, Dr. Parekh's first treatment was an injection in his spine in April 2024.

"He is the first person in the world to have received this treatment," says Dr. Oskarsson.

He would repeat the trip from Orlando to Jacksonville for the next two months, then placed on a three-month dosage.

"More than just ourselves, this would be a step forward for all the other people getting diagnosed with ALS; it would be something for them, hope," says Tejal.

One year after treatment started, the results are exciting to the Parekhs and Dr. Oskarsson.

"This is something that is truly new, and one day we will get there for everyone," says Dr. Oskarsson. "And when that happens, there's nothing that compares. It's a beautiful thing."

Back home, Dr. Parekh reflects on how this treatment has changed his outlook. His 25 years working in healthcare did not prepare him for what it would be like to receive care, let alone a therapy that may benefit his children one day.

"Not only has it made an impact on our lives, but honestly, it's made an impact on the way I practice because I realize now what patients need beyond healthcare," says Dr. Parekh.

The post (VIDEO) Florida dad receives first-in-world ALS treatment appeared first on Mayo Clinic News Network.

When Dr. Bobby Mukkamala found himself on the other side of the exam table, he relied on the cutting-edge surgical techniques at Mayo Clinic to get him back to his professional work. 

While presenting at a professional meeting, Dr. Bobby Mukkamala, normally an eloquent speaker, began speaking incoherently for about 90 seconds. 

"Given my age of 53 at the time, I thought it was a 'senior moment,'" says Dr. Mukkamala, an otolaryngologist and head and neck surgeon from Flint, Michigan. 

His colleagues suspected he was having a stroke and convinced Dr. Mukkamala to go to a nearby emergency department for evaluation. Doctors suggested he may have had a transient ischemic attack, or ministroke. They recommended an MRI when he returned home.

That scan revealed something far more serious: a brain tumor. His journey as a patient had begun — and it would ultimately lead him to Mayo Clinic. 

Finding the right brain cancer care

After sharing the news with his family, Dr. Mukkamala tapped into his professional network. "Within a week of my diagnosis, I had half a dozen Zoom calls with neurosurgeons around the country," he says. "They were all wonderful with similar but slightly different perspectives on how to approach my case."

One call, however, stood out — his conversation with Dr. Ian Parney, (pictured here) a neurosurgeon at Mayo Clinic in Rochester, Minnesota and member of Mayo Clinic Comprehensive Cancer Center.

Dr. Parney knew the tumor was large, complex and near critical speech areas in the brain. "It was important to Dr. Mukkamala to protect those areas," says Dr. Parney.   

Unlike other surgeons who recommended two brain surgeries, Dr. Parney recommended a single awake craniotomy with speech mapping. During the procedure, the patient answers questions, and brain activity is monitored. This helps surgeons avoid damaging parts of the brain responsible for speech. His extensive experience — about 200 similar brain tumor procedures per year — gave hope to Dr. Mukkamala that the single operation was the best choice.

"Dr. Parney spent time answering every question we had," Dr. Mukkamala says. "That is what healthcare should be. As soon as we got off the call, my wife and kids said, 'That's it. That's where you're going.'"

Using advanced surgical techniques to guide care

In December 2024, Dr. Mukkamala underwent an awake craniotomy with speech mapping. The surgical team also used an intraoperative MRI. This advanced imaging technique provides real-time, high-resolution MRI scans while the surgery is in progress. 

"We do an MRI during the procedure to get the most accurate image so that we can remove the tumor safely," says Dr. Parney. Integrating functional imaging into image-guided systems in the operating room is a technique that Dr. Parney's team develops and tests to improve patient safety. He also correlates these techniques with novel strategies such as intraoperative electrophysiological mapping (using electrodes or electrical simulation to identify and preserve functions) and fluorescence-guided resection.

In Dr. Mukkamala's case, as part of the speech mapping, Dr. Nuri Ince, a professor of neurosurgery and biomedical engineering at Mayo Clinic, provided a novel electrocorticography technique that showed critical areas of function without requiring direct cortical stimulation (electrical signals to the brain's outer layer), as is usually necessary.

Dr. Parney and his colleagues were able to remove more than 90% of Dr. Mukkamala's tumor without damaging the speech areas. Six weeks after surgery, he was once again speaking professionally and confidently to large groups.

Coordinating multidisciplinary cancer care

Dr. Mukkamala's cancerous brain tumor was a low-grade IDH-mutant astrocytoma. This type of brain tumor arises from astrocytes (a type of glial cell in the brain) and carries a mutation in the IDH (isocitrate dehydrogenase) gene. 

After surgery, Dr. Mukkamala met Dr. Ugur Sener, a neuro-oncologist at Mayo Clinic, who prescribed a new targeted drug to treat any remaining cancerous cells. The less toxic therapy allowed Dr. Mukkamala to avoid chemotherapy and radiation, which are standard treatments for brain cancer that can cause side effects such as fatigue and nausea. 

"We've built one of the largest brain tumor practices in the world here at Mayo," Dr. Parney says. "We have the right resources and the right teams in place to provide cutting-edge therapies and holistic care."

Bringing new 'tumor wisdom' to the bedside

While his life today looks much like it did before his diagnosis, Dr. Mukkamala says his perspective is forever changed by his experience. "I used to be more science than emotion, but I've learned there's room for both," he says. 

Dr. Mukkamala was alone when he received the news that he had cancer, much like most of his patients were when he delivered hard news. "It never occurred to me before that it was a problem to share a diagnosis when a patient was alone," Dr. Mukkamala says. He now tries to ensure his patients have support. 

It's one of the many lessons he attributes to "tumor wisdom." "My brain may be a little smaller," says Dr. Mukkamala, "but I think it's happier and wiser."

The post How advanced surgical skills returned a physician to the podium after brain cancer appeared first on Mayo Clinic News Network.

On this week's episode of Tomorrow's Cure, we explore brain-computer interfaces (BCIs), cutting-edge technologies that create direct communication pathways between the human brain and external devices. Once considered science fiction, BCIs are now transforming lives. 

The podcast episode features Dr. Jonathon Parker, epilepsy and functional neurosurgeon, assistant professor of neurosurgery and neuroscience, and director of the Neuroelectronics Research Lab at Mayo Clinic; and Dr. Allen Waziri, neuroscientist and neurosurgeon, and CEO and co-founder of iCE Neurosystems. Together, they discuss the science behind BCIs, current medical applications and the transformative possibilities they hold for the future.

BCIs offer groundbreaking possibilities in the treatment of neurological disorders, with the potential to restore mobility, communication and independence to people affected by severe neurologic injuries or conditions. Already, this technology is enabling users to control prosthetic limbs and digital interfaces through brain activity.

"The brain is a piece of hardware; the brain-computer interface is another piece of hardware we are connecting to the brain," says Dr. Parker. "We are used to communicating through speech, movement, understanding other sensory inputs, right? So this is digitizing those inputs to solve a problem." 

"BCIs, for several decades, is the translation of those electrical potentials that are coming off of the brain into something that we can understand on a computer side that will then functionalize whatever device — a robotic arm, a cursor on a screen, drive a wheelchair, so on and so forth," says Dr. Waziri.

BCIs are being used to assist people with neurological injuries that impair speech or movement. However, experts believe this technology has far greater potential. Beyond restoring motor function, BCIs could pave the way for continuous neurological monitoring and new forms of intervention, opening doors to transformative applications in brain health.

Dr. Parker emphasizes the broader clinical implications of the technology. "When delivered to clinicians so they can just monitor the brain signals overtime, (it) could have tremendous impact for epilepsy, depression, Alzheimer's — these conditions which are affecting huge swaths of our population. That's the future of this technology," he says. 

Don't miss this thought-provoking conversation on the evolving science of BCIs and the remarkable innovations that could redefine human-machine interaction. Listen to the latest episode of Tomorrow's Cure, and explore the full library of episodes and guests at tomorrowscure.com.

The post Tomorrow’s Cure: Mind meets machine — the future of neurological care appeared first on Mayo Clinic News Network.

Fifty-four-year-old Chris Sams of Arizona has been living with coccidioidomycosis, more commonly known as valley fever, for nearly a decade. When his symptoms worsened and standard treatments failed, he turned to Mayo Clinic's Cocci Clinic in Arizona — one of the few centers in the country that treats the most advanced and complicated cases.

Now, on a more aggressive antifungal treatment, Chris says Mayo Clinic's multidisciplinary team approach has made all the difference.

Valley fever can be serious, especially when it spreads beyond the lungs. In rare cases, as it did with Chris, the coccidioides infection can reach the brain and cause neurological damage, requiring intensive treatments.

Watch: When valley fever spreads - Meet Chris and his complex case

Journalists: Broadcast-quality video (3:00) is in the downloads at the end of this post. Please courtesy: "Mayo Clinic News Network." Read the script.

"I think I was biking up to 150 miles a week. I was biking quite a bit, lot of wind, lot of sand, lot of dust," says Chris.

That dust may have carried fungal spores that infected Chris with valley fever — a lung infection caused by breathing in spores that live in the soil but can become airborne.

"I was always sick. I was worn down. I lost a massive amount of weight. And that's really what threw us over the edge, is that something was going wrong," he says.

He ended up in the hospital.

"They put me in isolation floor because they didn't know if I had cancer, tuberculosis or if it was the continuance of valley fever," he recalls.

Tests confirmed it was valley fever, also known as coccidioidomycosis or cocci. The majority of people who get cocci recover well on their own, but in a small number of people, like Chris, the fungal spores can spread beyond the lungs, causing severe or even life-threatening symptoms.

"Less than 5% of people have it spread outside of the lung. It can go to many different places: bones, soft tissues and potentially the central nervous system. And, unfortunately, while it is a small percentage of people, when it does get into the central nervous system, it causes potentially devastating consequences," says Dr. Marie Grill, a Mayo Clinic neurologist.

In Chris' case, the spores had spread to his brain. That's when he sought help at Mayo Clinic's Cocci Clinic in Arizona, where a multidisciplinary team of specialists treats the most serious and complex cases of valley fever.

"Now we have our roadmap. We have a direction on where we're going — because otherwise, everything is just spiraling out of control," says Chris.

He began undergoing a special treatment delivered every few weeks right to his brain.

"It's an antifungal medication which can be delivered intravenously but can also be delivered directly into what we call the intrathecal space, which is essentially directly into the spaces where we have the spinal fluid," explains Dr. Grill.

The good news is doctors say Chris is showing signs of improvement.

"They think that there is an end in sight and hopefully we will wean off the intrathecal treatments. I mean, we've weaned it down to every two weeks," he says.

Doctors have yet to determine how long the treatments will need to continue, but Chris is confident he's heading in the right direction, with the right team.

"I have the best committed team around that talk to me, care about me, talk to me as a person and want me fixed."

While the Cocci Clinic cares for patients with serious cases of valley fever, Mayo Clinic is also advancing the field with a faster, more accurate test to speed up diagnosis and treatment.

Related post:

• (VIDEO) Faster diagnosis for valley fever: New test in development

The post (VIDEO) When valley fever spreads: Meet Chris and his complex case appeared first on Mayo Clinic News Network.

Just one day after undergoing brain shunt surgery at Mayo Clinic, 75-year-old Minoo Press put his wheelchair aside and walked out of the hospital on his own. For the first time in two years, his mind was clear. His balance had returned. He was no longer losing control of his bladder. 

The significant turnaround followed two years of steady cognitive and physical decline. A retired engineer known for his sharp mind and independence, Press gradually withdrew from daily life. Even simple routines became impossible. 

He visited leading medical centers across the country, undergoing spinal taps, surgical procedures and advanced imaging to evaluate for conditions ranging from Alzheimer's disease to Parkinson's. 

Some clinicians at those institutions also considered normal pressure hydrocephalus, a condition in which excess fluid builds up in the brain. But because Mr. Press' symptoms overlapped with signs of neurodegenerative disease, the doctors could not confirm the diagnosis or recommend surgery. They told him there was nothing more they could do. 

From rapid diagnosis to life-changing care

After an exhaustive search for answers, Press' family brought him to Mayo Clinic where he was evaluated by Dr. David Jones, a neurologist and director of Mayo Clinic's Neurology Artificial Intelligence Program.   

Dr. Jones used an innovative artificial intelligence tool developed by his team, called StateViewer. The tool works with a widely available brain scan known as fluorodeoxyglucose positron emission tomography, or FDG-PET, comparing a patient's brain activity to thousands of confirmed dementia cases. It highlights patterns linked to nine types of the disease — from Alzheimer's and frontotemporal dementia to less common forms with overlapping symptoms. 

In a recent study published in Neurology, the tool identified the correct dementia type in 88% of cases and helped clinicians interpret scans up to three times more accurately and twice as fast as standard methods.  

In Press' case, the tool helped Dr. Jones rule out Alzheimer's and other types of dementia. That was the turning point.  

With neurodegenerative disease ruled out, Dr. Jones diagnosed Press with normal pressure hydrocephalus and confirmed that he was a candidate for a shunt procedure to relieve the pressure on his brain and potentially reverse the symptoms.  

A last-minute surgical cancellation made it possible for Press to have the procedure that same week.

Within three days at Mayo Clinic, he had a clear diagnosis, a treatment plan and underwent brain surgery to place a shunt that would drain excess fluid from his brain. The procedure was performed by Dr. Ben Elder, a neurosurgeon and clinician-scientist.  

Press, who traveled from Chicago, noticed immediate improvements. His thinking was sharper, his steps steadier and he felt like himself again. 

A clear mind, steady steps and hope

Dr. Jones says Press' case highlights the promise of combining AI with clinical care to accelerate diagnosis, scale expert clinical knowledge and help guide treatment planning.  

"When you're looking at overlapping symptoms, it's easy to miss the underlying cause," Dr. Jones says. "StateViewer gave us the clarity we needed to make an informed diagnosis and take action." 

Press continues physical therapy and says he's improving every day. He hopes his story can help others who are navigating the same often misdiagnosed and debilitating condition. 

"I can enjoy time with my family again and I can go out with my friends. I can even do my own taxes. These are the moments I thought I had lost forever," Mr. Press says. "Mayo Clinic gave me my life back." 

Related article:

Mayo Clinic's AI tool identifies 9 dementia types, including Alzheimer's, with one scan

Mayo Clinic researchers have developed a new artificial intelligence (AI) tool that helps clinicians identify brain activity patterns linked to nine types of dementia, including Alzheimer's disease, using a single, widely available scan — a transformative advance in early, accurate diagnosis. Read more.

The post How a Mayo Clinic neurologist used AI to help restore a patient’s health appeared first on Mayo Clinic News Network.

ROCHESTER, Minn. — Mayo Clinic researchers have developed a new artificial intelligence (AI) tool that helps clinicians identify brain activity patterns linked to nine types of dementia, including Alzheimer's disease, using a single, widely available scan — a transformative advance in early, accurate diagnosis. 

The tool, StateViewer, helped researchers identify the dementia type in 88% of cases, according to research published online on June 27, 2025, in Neurology, the medical journal of the American Academy of Neurology. It also enabled clinicians to interpret brain scans nearly twice as fast and with up to three times greater accuracy than standard workflows. Researchers trained and tested the AI on more than 3,600 scans, including images from patients with dementia and people without cognitive impairment. 

This innovation addresses a core challenge in dementia care: identifying the disease early and precisely, even when multiple conditions are present. As new treatments emerge, timely diagnosis helps match patients with the most appropriate care when it can have the greatest impact. The tool could bring advanced diagnostic support to clinics that lack neurology expertise. 

The rising toll of dementia 

Dementia affects more than 55 million people worldwide, with nearly 10 million new cases each year. Alzheimer's disease, the most common form, is now the fifth-leading cause of death globally. Diagnosing dementia typically requires cognitive tests, blood draws, imaging, clinical interviews and specialist referrals. Even with extensive testing, distinguishing conditions such as Alzheimer's, Lewy body dementia and frontotemporal dementia remains challenging, including for highly experienced specialists. 

StateViewer was developed under the direction of David Jones, M.D., a Mayo Clinic neurologist and director of the Mayo Clinic Neurology Artificial Intelligence Program.  

"Every patient who walks into my clinic carries a unique story shaped by the brain's complexity," Dr. Jones says. "That complexity drew me to neurology and continues to drive my commitment to clearer answers. StateViewer reflects that commitment — a step toward earlier understanding, more precise treatment and, one day, changing the course of these diseases." 

To bring that vision to life, Dr. Jones worked alongside Leland Barnard, Ph.D., a data scientist who leads the AI engineering behind StateViewer. 

"As we were designing StateViewer, we never lost sight of the fact that behind every data point and brain scan was a person facing a difficult diagnosis and urgent questions," Dr. Barnard says. "Seeing how this tool could assist physicians with real-time, precise insights and guidance highlights the potential of machine learning for clinical medicine." 

Turning brain patterns into clinical insight 

The tool analyzes a fluorodeoxyglucose positron emission tomography (FDG-PET) scan, which shows how the brain uses glucose for energy. It then compares the scan to a large database of scans from people with confirmed dementia diagnoses and identifies patterns that match specific types, or combinations, of dementia. 

Alzheimer's typically affects memory and processing regions, Lewy body dementia involves areas tied to attention and movement, and frontotemporal dementia alters regions responsible for language and behavior. StateViewer displays these patterns through color-coded brain maps that highlight key areas of brain activity, giving all clinicians, even those without neurology training, a visual explanation of what the AI sees and how it supports the diagnosis. 

Mayo Clinic researchers plan to expand the tool's use and will continue evaluating its performance in a variety of clinical settings. 

For a complete list of authors, disclosures and funding, review the study.

### 

About Mayo Clinic 
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news. 

Media contact:  

• Tia Ford, Mayo Clinic Communications, newsbureau@mayo.edu 

The post Mayo Clinic’s AI tool identifies 9 dementia types, including Alzheimer’s, with one scan  appeared first on Mayo Clinic News Network.